Conodiparine D






Names

    • Conodiparine D

Attributes

  • Canonical SMILES

    C/C=C/1\CN([C@H]2CC3=C([C@H](C[C@@H]1[C@]2(CO)C(=O)OC)C4=C(C=CC5=C4NC6=C5CCN7C[C@@H]8C[C@@H]([C@H]7[C@]6(C8)C(=O)OC)C(=O)C)OC)NC9=CC=CC=C39)C

  • InChI

    InChI=1S/C44H52N4O7/c1-7-25-21-47(3)35-18-30-26-10-8-9-11-33(26)45-37(30)31(17-32(25)44(35,22-49)42(52)55-6)36-34(53-4)13-12-27-28-14-15-48-20-24-16-29(23(2)50)40(48)43(19-24,41(51)54-5)39(28)46-38(27)36/h7-13,24,29,31-32,35,40,45-46,49H,14-22H2,1-6H3/b25-7+/t24-,29-,31-,32+,35+,40+,43-,44+/m1/s1

  • Molecule Class: Alkaloids
  • TPSA: 137.19000000000003
  • #RotBonds: 6
  • MW: 748.9210000000003
  • HBD: 3
  • HBA: 9
  • logP: 5.030400000000005
  • Chemical Formula: C44H52N4O7


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. corymbosa Malaysia, China 1679252 GK604

External Databases


References

  • Conodiparines A-D, new bisindoles from Tabernaemontana. Reversal of vincristine-resistance with cultured cells. Bioorg Med Chem Lett, 1998 (PMID 9873417).
  • New bisindole alkaloids from Tabernaemontana corymbosa. J Nat Prod, 2003 (PMID 12542336).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Cytotoxicity

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.


Predicted ADMET Properties

    Property Model Name Predicted Value

    Absorption Caco-2 (logPaap) -6.05
    Human Oral Bioavailability 20% Non-Bioavailable
    Human Intestinal Absorption Non-Absorbed
    Madin-Darby Canine Kidney 75.92
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability 10706.72

    Distribution Blood-Brain Barrier (Central Nervous System) -3.72
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 1.03
    Plasma Protein Binding 86.71
    Steady State Volume of Distribution 3.59

    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Non-Substrate
    CYP 3A4 Inhibitor Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Inhibitor

    Excretion Clearance 8.7
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs

    Toxicity AMES Mutagenesis Safe
    Avian Toxic
    Bee Toxic
    Bioconcentration Factor -253.12
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -1.2
    Liver Injury II Toxic
    hERG Blockers Toxic
    Daphnia Maga 6.58
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis -19429269.18
    Rat (Acute) 2.91
    Rat (Chronic Oral) 2.31
    Fathead Minnow 24527.72
    Respiratory Disease Toxic
    Skin Sensitisation Safe
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe

    General Properties Boiling Point 2181085.96
    Hydration Free Energy -2.92
    Log(D) at pH=7.4 4.68
    Log(P) 3.29
    Log S -5.17
    Log(Vapor Pressure) -71748.46
    Melting Point 287.92
    pKa Acid -472.67
    pKa Basic 5.42